Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Dry Eye Syndrome Companies

ID: MRFR/Pharma/4139-HCR
90 Pages
Vikita Thakur
Last Updated: February 16, 2025

Dry eye syndrome is a common eye disorder characterized by insufficient tear production or poor-quality tears, leading to discomfort, irritation, and potential damage to the surface of the eye. Companies specializing in dry eye syndrome typically focus on the development and commercialization of products and therapies aimed at diagnosing, treating, and managing dry eye conditions. 

Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Dry Eye Syndrome Market

Dry Eye Syndrome Key Companies
ย 
Latest Dry Eye Syndrome Companies Update

Jan 2024Alcon (Switzerland) Received positive topline results from Phase 3 trials for AR-15512, a novel investigational therapy for DES with potential to alleviate inflammation and stabilize the tear film.Launched their innovative VerifEyeโ„ข Anterior Segment OCT system, enabling real-time visualization of corneal and meibomian gland structures for improved DES diagnosis and treatment planning.

Santen Pharmaceutical Co., Ltd. (Japan) Announced successful Phase 2 results for MK-5351, a first-in-class topical therapy for DES targeting neurogenic inflammation, potentially offering a novel treatment approach.Introduced their innovative TearCareยฎ LifeStyle Mask, combining gentle heat and pulsation to improve meibomian gland function and alleviate DES symptoms.

Paragon Medical (US) Launched their novel HydraLensยฎ contact lens for DES patients, featuring advanced moisture retaining technology for lasting comfort and improved tear film stability.Partnered with leading ophthalmologists to develop specialized contact lens fitting protocols for individuals with DES.

Johnson & Johnson (US) Received FDA approval for their Tecnis Symfonyยฎ Extended IOL, offering wider range of vision and potentially reducing dependence on reading glasses for cataract patients with DES.Continued advancements in their iTEARยฎ technology for developing next-generation artificial tears with improved efficacy and patient preference.

Acuity Brands (US) Introduced their EyeSiteProโ„ข lighting solutions designed to reduce screen glare and fatigue, potentially benefiting individuals with DES experiencing discomfort from digital devices.Collaborated with eye care professionals to promote awareness about the negative impact of harmful blue light on DES symptoms.

List of Dry Eye Syndrome Key Companies in the Market

  • Allergan (Republic of Ireland)
  • Novartis AG (Switzerland)
  • Otsuka Pharmaceutical Co. Ltd. (Japan)
  • Valent Pharmaceuticals (Canada)
  • Johnson & Johnson Vision (US)
  • Acadia Pharmaceuticals (US)
  • Allostera Pharma (Canada)
  • I-Med Pharma Inc. (Canada)